Simcere Pharmaceutical

2096 · HKEX

Public Market Listing

2096HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Simcere Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(9 total)
9Total Assets
0Approved
7Phase 3 / Filed
2Phase 1–2 / Early
9Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
Phase 3
ALK;ROS1Small molecule
Non-Small Cell Lung Cancer
Phase 3
VEGFR2 (KDR/Flk-1) on vascular endothelial cellsProtein / enzyme therapeutic
Non-Small Cell Lung Cancer
Phase 3
PD-L1Monoclonal antibody
HIVNon-Small Cell Lung CancerChronic Hepatitis BEndometrial Cancer
Phase 3
NF-kB
Rheumatoid Arthritis
Phase 3
JAK1/2Small molecule
Atopic Dermatitis
Phase 3
IL-4R-alphaMonoclonal antibody
Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthma
Phase 3
JAK1Small molecule
Atopic DermatitisRheumatoid Arthritis
Phase 1
Broad anti-angiogenic activityProtein / enzyme therapeutic
Non-Small Cell Lung Cancer
Phase 1
GPRC5D x BCMA x CD3Multispecific antibody
Multiple Myeloma

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
ZemprocitinibPhase 3Ankylosing Spondylitis
Est. primary completion 2026-11 · NCT07237568 · CT.gov ↗
What to watch
December 2026 (3)
EnvafolimabPhase 1/2Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
Est. primary completion 2026-12 · NCT05024214 · CT.gov ↗
What to watch
EnvafolimabPhase 2Advanced Endometrial Cancer
Est. primary completion 2026-12 · NCT05112991 · CT.gov ↗
What to watch
RademikibartPhase 3Asthma; Eosinophilic
Est. primary completion 2026-12-31 · NCT06488755 · CT.gov ↗
What to watch
2027 (2)
August 2027 (1)
EnvafolimabPhase 2Solid Tumor
Est. primary completion 2027-08-30 · NCT04891198 · CT.gov ↗
What to watch
December 2027 (1)
EnvafolimabPhase 3Non-small Cell Lung Cancer
Est. primary completion 2027-12-30 · NCT06123754 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
EnvafolimabPhase 2Biliary Tract Neoplasms
Est. primary completion 2029-06 · NCT04910386 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(9)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 November 2026Filing acceptedZemprocitinibChina accepts the zemprocitinib application in rheumatoid arthritis
CN, NMPA · Lynk Pharmaceuticals · Source ↗
30 September 2026Topline resultRademikibartPhase 2 Seabreeze STAT COPD topline results
Connect Biopharma · Source ↗
15 September 2026Topline resultRademikibartPhase 2 acute asthma exacerbation topline results
Connect Biopharma · Source ↗
1 June 2026Filing acceptedpumecitinibChina NDA for pumecitinib gel in atopic dermatitis accepted by NMPA CDE (reported)
CN, NMPA (CDE) · Prime Gene Therapeutics (Beijing Puqi Medical) · Source ↗
10 April 2026Filing acceptedzemprocitinib (LNK01001)Zemprocitinib NDA accepted by China's NMPA (CDE)
CN, NMPA · Lynk Pharmaceuticals · Source ↗
30 March 2026Topline resultRademikibartRADIANT-AD (NCT06477835) Phase 3 met its primary endpoint
Simcere Pharmaceutical Group Limited (2096.HK) · Source ↗
12 January 2026Topline resultLNK01001 (zemprocitinib)COURAGE-RA (NCT06276998) Phase 3 met its primary endpoint
China · Simcere Pharmaceutical Group · Source ↗
9 July 2025Filing submittedRademikibartSimcere submits rademikibart NDA in China for atopic dermatitis
CN, NMPA · Source ↗
8 July 2025Filing acceptedRademikibartNMPA accepts Simcere's NDA for rademikibart in atopic dermatitis
CN, NMPA · Simcere Pharmaceutical · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.1B———report ↗